(Q40145996)

17 September 2017

1 reference

title

Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis (English)

1 reference

17 September 2017

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

author name string

K. V. Honn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6338880

2 October 2023

W. D. Busse

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6338880

2 October 2023

B. F. Sloane

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6338880

2 October 2023

language of work or name

English

0 references

publication date

1 January 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0006295283906445?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

https://api.elsevier.com/content/article/PII:0006295283906445?httpAccept=text/plain

2 October 2023

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

published in

Biochemical Pharmacology

1 reference

17 September 2017

volume

32

1 reference

17 September 2017

issue

1

1 reference

17 September 2017

page(s)

1-11

1 reference

17 September 2017

2

38

2651

Fidler

1978

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Rationale and experimental design for the va cooperative study of anticoagulation (warfarin) in the treatment of cancer

2 October 2023

4

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Malignancy and haemostasis

2 October 2023

5

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Role of platelets in tumor cell metastases

2 October 2023

6

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The effect of heparin on the initial phase of metastasis formation

2 October 2023

8

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The Biology of Cancer Invasion and Metastasis

2 October 2023

12

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The significance of the circulating cancer cell

2 October 2023

13

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Invasion of Liver Tissue by Tumor Cells and Leukocytes: Comparative Ultrastructure

2 October 2023

16

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Effects of prior injection of Walker cancer cells in the rat on the lung-retention pattern of a second dose

2 October 2023

18

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Prostacyclin: a potent antimetastatic agent

2 October 2023

19

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

21

21

38

Zeidman

1961

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Platelet—tumor-cell interactions in mice. The role of platelets in the spread of malignant disease

2 October 2023

23

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases

2 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

25

38

2950

Gasic

1978

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The role of blood platelets in experimental metastases

2 October 2023

26

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Aggregation of activated platelets with Walker 256 carcinoma cells

2 October 2023

28

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

29

40

1217

Hara

1980

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Studies on mechanisms involved in metastasis formation from circulating tumor cells. Factors influencing tumor cell lodgement during normal and post-traumatic conditions

2 October 2023

31

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

32

41

4535

Pearlstein

1981

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Idiosyncratic platelet responses to human tumour cells.

2 October 2023

33

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Metastatic Potential Is Positively Correlated with Cell Surface Sialylation of Cultured Murine Tumor Cell Lines

2 October 2023

35

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems

2 October 2023

36

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Increased Incidence of Pulmonary Metastases After Celiotomy: Counteraction by Heparin

2 October 2023

37

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice

2 October 2023

38

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Decrease in pulmonary metastases: potentiation of nitrogen mustard effect by heparin and fibrinolysin

2 October 2023

39

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

40

27

421

Fisher

1967

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Evidence for effects of heparin on cell surfaces influencing experimental metastases

2 October 2023

41

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Growth and metastasis of the Lewis lung carcinoma in mice defibrinated with batroxobin

2 October 2023

42

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL)

2 October 2023

44

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Aspirin and tumour metastasis

2 October 2023

45

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Anti-metastatic effect of aspirin

2 October 2023

46

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cells

2 October 2023

47

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Inhibition of platelet prostaglandin synthetase by oral aspirin

2 October 2023

48

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Prostacyclin: Homeostatic Regulator or Biological Curiosity?

2 October 2023

55

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Present concepts on the mechanisms of platelet aggregation

2 October 2023

56

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour.

2 October 2023

60

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor

2 October 2023

61

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

2 October 2023

63

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Biotransformation and cardiovascular effects of arachidonic acid in the dog

2 October 2023

65

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation

2 October 2023

66

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men

2 October 2023

67

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Generation of prostacyclin by lungs in vivo and its release into the arterial circulation

2 October 2023

68

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Prostacyclin is a circulating hormone

2 October 2023

69

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Respiratory movements alter the generation of prostacyclin and thromboxane A2 in isolated rat lungs: the influence of arachidonic acid-pathway inhibitors on the ratio between pulmonary prostacyclin and thromboxane A2

2 October 2023

70

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Prostacyclin and thromboxane A2 release in isolated rat lungs

2 October 2023

71

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Albumins stabilize prostaglandin I2

2 October 2023

72

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Is prostacyclin a physiologically important circulating anti-platelet agent?

2 October 2023

73

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Measurement of circulating prostacyclin

2 October 2023

74

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Prostacyclin is not a circulating hormone

2 October 2023

75

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Estimated rate of prostacyclin secretion into the circulation of normal man

2 October 2023

76

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Stability of prostaglandin I2 in human blood

2 October 2023

78

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism?

2 October 2023

80

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium

2 October 2023

81

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Biochimica et Biophysica Acta

2 October 2023

87

560

135

Roos

1979

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes

2 October 2023

88

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

The production of the arachidonate metabolite HETE in vascular tissue

2 October 2023

89

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Trapped blood elements within the decidua of the rat pregnant uterus generate a lipoxygenase product(s) which inhibits myometrial prostacyclin synthesis

2 October 2023

90

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma

2 October 2023

93

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound

2 October 2023

96

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575

2 October 2023

97

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Nafazatrom (Bay g 6575) inhibition of tumor cell lipoxygenase activity and cellular proliferation

2 October 2023

99

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

9,11-Iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A2 synthetase inhibitor

2 October 2023

102

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Cathepsins BI and D. Action on human cartilage proteoglycans.

2 October 2023

104

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Cathepsin B1. A lysosomal enzyme that degrades native collagen

2 October 2023

105

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation

2 October 2023

106

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Cellular detachment by purified lysosomal cathepsin B

2 October 2023

107

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas

2 October 2023

108

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

109

40

550

Recklies

1980

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Elevated serum cathepsin B1-like activity in women with neoplastic disease

2 October 2023

111

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Lysosomal cathepsin B-like activity: mobilization in prereplicative and neoplastic epithelial cells.

2 October 2023

112

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

114

42

980

Sloane

1982

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

116

40

3281

Dobrossy

1980

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Some mechanisms involved in cancer cell detachment by necrotic material

2 October 2023

117

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

120

37

4291

Meistrich

1977

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Lysosomal cathepsin B: correlation with metastatic potential

2 October 2023

121

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

A proteolytic procoagulant associated with malignant transformation.

2 October 2023

123

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

A factor X-activating cysteine protease from malignant tissue

2 October 2023

124

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Proteolysis, fibrinolysis, and coagulation. Significance in thrombolytic therapy

2 October 2023

125

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin

2 October 2023

126

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Primary structure study of rat liver cathepsin B -- a striking resemblance to papain

2 October 2023

127

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates

2 October 2023

128

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Rapid inactivation of cathepsin L by Z-Phe-PheCHN2 and Z-Phe-AlaCHN2

2 October 2023

130

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

131

42

1026

Recklies

1982

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

A latent thiol proteinase from ascitic fluid of patients with neoplasia

2 October 2023

132

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

Inhibition by alpha-macroglobulin and other serum proteins

2 October 2023

133

1 reference

https://api.crossref.org/works/10.1016/0006-2952(83)90644-5

2 October 2023

Identifiers

1 reference

17 September 2017

1 reference